About Biohaven Pharm (NYSE:BHVN)
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.
Industry, Sector and Symbol:
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Sector: Medical
- Symbol: NYSE:BHVN
- Previous Symbol: NASDAQ:BHVN
- CUSIP: N/A
- Web: www.biohavenpharma.com
- Current Ratio: 11.91%
- Quick Ratio: 11.91%
- Employees: 12
- Outstanding Shares: 36,020,000
Frequently Asked Questions for Biohaven Pharm (NYSE:BHVN)
What is Biohaven Pharm's stock symbol?
Biohaven Pharm trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."
When will Biohaven Pharm make its next earnings announcement?
Where is Biohaven Pharm's stock going? Where will Biohaven Pharm's stock price be in 2017?
5 equities research analysts have issued 12 month price targets for Biohaven Pharm's stock. Their predictions range from $30.00 to $54.00. On average, they expect Biohaven Pharm's stock price to reach $40.80 in the next twelve months. View Analyst Ratings for Biohaven Pharm.
What are Wall Street analysts saying about Biohaven Pharm stock?
Here are some recent quotes from research analysts about Biohaven Pharm stock:
- 1. Needham & Company LLC analysts commented, "Biohaven reported 3Q17 financial results and we spoke w/ mgmt for an update. Rimegepant Phase 3 trials in Acute Migraine are nearing completion of enrollment and mgmt reiterated guidance for top-line results in 1Q18. We expect a positive outcome based on strength of Phase 2b data. Biohaven recently initiated a registration bioequivalence trial of BHV-0223 in Amyotrophic Lateral Sclerosis (ALS) and we believe results will be available in early 2018. We expect company to submit 505(b)(2) application (oral riluzole disintegrating tablet) by mid-2017. BHV5000 IND submission is on track, but BH3500 has been pushed into 2018 because of technical regulatory matters tied to manufacturing. Reiterate BUY, w/ expectations for upside around rimegepant Phase 3 outcome." (11/15/2017)
- 2. According to Zacks Investment Research, "Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. " (10/17/2017)
Are investors shorting Biohaven Pharm?
Biohaven Pharm saw a increase in short interest during the month of October. As of October 13th, there was short interest totalling 1,985,275 shares, an increase of 143.5% from the September 29th total of 815,466 shares. Based on an average daily trading volume, of 341,709 shares, the days-to-cover ratio is presently 5.8 days. Approximately 10.1% of the shares of the company are sold short.
Who are some of Biohaven Pharm's key competitors?
Some companies that are related to Biohaven Pharm include Global Blood Therapeutics (GBT), Intrexon Corporation (XON), Genus plc (GNS), Medpace Holdings (MEDP), Esperion Therapeutics (ESPR), Editas Medicine (EDIT), Arena Pharmaceuticals (ARNA), Momenta Pharmaceuticals (MNTA), Genomic Health (GHDX), ImmunoGen (IMGN), Albany Molecular Research (AMRI), Enanta Pharmaceuticals (ENTA), Heron Therapeutics (HRTX), Cellectis S.A. (CLLS), BeyondSpring (BYSI), Abeona Therapeutics (ABEO), Crispr Theraptc (CRSP) and ANI Pharmaceuticals (ANIP).
Who are Biohaven Pharm's key executives?
Biohaven Pharm's management team includes the folowing people:
- Declan Doogan M.D., Independent Chairman of the Board (Age 65)
- Vlad Coric M.D., Chief Executive Officer, Director (Age 46)
- James Engelhart, Chief Financial Officer (Age 53)
- Charles Conway Ph.D., Chief Scientific Officer (Age 55)
- Kimberly Gentile, Vice President - Clinical Operations (Age 51)
- Robert Berman M.D., Chief Medical Officer (Age 54)
- John Tilton, Chief Commercial Officer (Age 49)
- Gregory H. Bailey M.D., Director (Age 61)
- John W. Childs, Director (Age 75)
- Julia P. Gregory, Director (Age 64)
When did Biohaven Pharm IPO?
(BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.
When did the company's lock-up period expire?
Biohaven Pharm's lock-up period expired on Tuesday, October 31st. Biohaven Pharm had issued 9,900,000 shares in its IPO on May 4th. The total size of the offering was $168,300,000 based on an initial share price of $17.00. Since the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.
Who owns Biohaven Pharm stock?
Biohaven Pharm's stock is owned by a variety of of institutional and retail investors. Top institutional investors include VHCP Management II LLC (4.63%), Eagle Asset Management Inc. (2.55%), Janus Henderson Group PLC (1.92%), JPMorgan Chase & Co. (1.33%), Stifel Financial Corp (1.16%) and Perceptive Advisors LLC (0.85%). Company insiders that own Biohaven Pharm stock include Albert Cha, James Engelhart, John Tilton, Kimberly Gentile, Robert Berman and Vlad Coric. View Institutional Ownership Trends for Biohaven Pharm.
Who bought Biohaven Pharm stock? Who is buying Biohaven Pharm stock?
Biohaven Pharm's stock was purchased by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Eagle Asset Management Inc., Janus Henderson Group PLC, JPMorgan Chase & Co., Stifel Financial Corp, Perceptive Advisors LLC, Emerald Advisers Inc. PA and Citadel Advisors LLC. Company insiders that have bought Biohaven Pharm stock in the last two years include Albert Cha, James Engelhart and Robert Berman. View Insider Buying and Selling for Biohaven Pharm.
How do I buy Biohaven Pharm stock?
Shares of Biohaven Pharm can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biohaven Pharm's stock price today?
One share of Biohaven Pharm stock can currently be purchased for approximately $25.61.
How big of a company is Biohaven Pharm?
Biohaven Pharm has a market capitalization of $876.35 million. Biohaven Pharm employs 12 workers across the globe.
How can I contact Biohaven Pharm?
Biohaven Pharm's mailing address is 234 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.
MarketBeat Community Rating for Biohaven Pharm (NYSE BHVN)MarketBeat's community ratings are surveys of what our community members think about Biohaven Pharm and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Biohaven Pharm (NYSE:BHVN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$40.80 (59.31% upside)|
Consensus Price Target History for Biohaven Pharm (NYSE:BHVN)
Analysts' Ratings History for Biohaven Pharm (NYSE:BHVN)
(Data available from 11/18/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/15/2017||Needham & Company LLC||Reiterated Rating||Buy||$36.00||N/A|
|10/3/2017||William Blair||Reiterated Rating||Outperform||Low|
|10/3/2017||Morgan Stanley||Reiterated Rating||Overweight -> Overweight||$47.00 -> $38.00||High|
|9/12/2017||Piper Jaffray Companies||Reiterated Rating||Buy||$54.00||Low|
|5/30/2017||Barclays PLC||Initiated Coverage||Overweight -> Overweight||$30.00||High|
Earnings History for Biohaven Pharm (NYSE:BHVN)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Biohaven Pharm (NYSE:BHVN)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Biohaven Pharm (NYSE:BHVN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Biohaven Pharm (NYSE BHVN)
Institutional Ownership Percentage: 44.03%
Insider Trades by Quarter for Biohaven Pharm (NYSE BHVN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/14/2017||Robert Berman||Insider||Sell||160,000||$25.76||$4,121,600.00|| |
|11/10/2017||James Engelhart||CFO||Sell||30,538||$26.58||$811,700.04|| |
|11/9/2017||Robert Berman||Insider||Sell||27,423||$26.60||$729,451.80|| |
|11/1/2017||John Tilton||Insider||Sell||30,000||$29.25||$877,500.00|| |
|11/1/2017||Kimberly Gentile||VP||Sell||5,000||$29.28||$146,400.00|| |
|11/1/2017||Vlad Coric||CEO||Sell||150,000||$29.41||$4,411,500.00|| |
|5/9/2017||Albert Cha||Director||Buy||470,000||$17.00||$7,990,000.00|| |
|5/9/2017||James Engelhart||CFO||Buy||2,500||$17.00||$42,500.00|| |
|5/9/2017||Robert Berman||Insider||Buy||50||$17.00||$850.00|| |
Headline Trends for Biohaven Pharm (NYSE:BHVN)
Latest Headlines for Biohaven Pharm (NYSE BHVN)
Biohaven Pharm (NYSE BHVN) Chart for Saturday, November, 18, 2017